Kurt Schalper, MD, PhD
Associate Professor of PathologyCards
About
Research
Overview
Medical Research Interests
Breast Neoplasms; Pathology
Publications
2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, Le J, Montesion M, Palmer R, Jahchan N, Juan J, Min C, Yu Y, Pan X, Arbour K, Vokes N, Schmidt S, Molkentine D, Owen D, Memmott R, Patil P, Marmarelis M, Awad M, Murray J, Hellyer J, Gainor J, Dimou A, Bestvina C, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian M, Sacher A, Lau S, Saltos A, Rotow J, Johnson R, Liu C, Stewart T, Goldberg S, Killam J, Walther Z, Schalper K, Davies K, Woodcock M, Anagnostou V, Marrone K, Forde P, Ricciuti B, Venkatraman D, Van Allen E, Cummings A, Goldman J, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok J, Segal J, Ritterhouse L, Neal J, Lacroix L, Elamin Y, Negrao M, Le X, Lam V, Lewis W, Kemp H, Carter B, Roth J, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula A, Parra Cuentas E, Behrens C, Wistuba I, Zhang J, Blumenschein G, Gay C, Byers L, Gibbons D, Tsao A, Lee J, Bivona T, Camidge D, Gray J, Leighl N, Levy B, Brahmer J, Garassino M, Gandara D, Garon E, Rizvi N, Scagliotti G, Wolf J, Planchard D, Besse B, Herbst R, Wakelee H, Pennell N, Shaw A, Jänne P, Carbone D, Hellmann M, Rudin C, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson M, Wong K, Huang A, Winslow M, Rosen M, Winters I, Papadimitrakopoulou V, Cascone T, Jewsbury P, Heymach J. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 2025, 639: e19-e19. PMID: 40016449, PMCID: PMC11903295, DOI: 10.1038/s41586-025-08767-9.Peer-Reviewed Original ResearchSelective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500.
Appleman V, Matsuda A, Ganno M, Zhang D, Rosentrater E, Maldonado Lopez A, Porciuncula A, Hatten T, Christensen C, Merrigan S, Lee H, Lee M, Wang C, Dong L, Huang J, Iartchouk N, Wang J, Xu H, Yoneyama T, Piatkov K, Haridas S, Harbison C, Gregory R, Parent A, Lineberry N, Arendt C, Schalper K, Abu-Yousif A. Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500. Cancer Immunology Research 2025 PMID: 39918395, DOI: 10.1158/2326-6066.cir-24-0103.Peer-Reviewed Original ResearchIntratumoral myeloid cellsMyeloid cellsTumor microenvironmentImmune responseCCR2+ cellsI interferonImmunosuppressive myeloid populationsImmune activation in vitroImmune cell markersLocal immune activationMurine tumor modelsAdaptive immune responsesAntibody drug conjugatesType I interferonAntitumor immunityInnate immune responseMyeloid populationsSTING agonistsSolid tumorsCCR2 proteinImmune activationTumor modelCell markersHuman tumorsAdaptive immunityA Phase I/IB Trial of Pembrolizumab and Trametinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Enriched for KRAS Mutations
Riess J, Lara M, Luxardi G, de Rodas M, Shimoda M, Kelly K, Lara P, Beckett L, Monjazeb A, Schalper K, Maverakis E, Gandara D. A Phase I/IB Trial of Pembrolizumab and Trametinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Enriched for KRAS Mutations. JTO Clinical And Research Reports 2025, 100806. DOI: 10.1016/j.jtocrr.2025.100806.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerMEK inhibitionAdverse eventsProgressive diseaseKRAS mutationsMyeloid-derived suppressor cellsTrametinib 2 mgDose-escalation studyPlatinum-based chemotherapyImmune cell alterationsTumor immune microenvironmentPhase 1 studyCell lung cancerHigh-parameter flow cytometryArm BEscalation studyPartial responseArm ASuppressor cellsImmune microenvironmentPembrolizumabTrametinibQuantitative immunofluorescenceLung cancerBiological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Lopez de Rodas M, Villalba-Esparza M, Sanmamed M, Chen L, Rimm D, Schalper K. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nature Reviews Clinical Oncology 2025, 22: 163-181. PMID: 39820025, DOI: 10.1038/s41571-024-00984-x.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesImmune-checkpoint inhibitorsTumor-infiltrating lymphocyte subpopulationsClinical significance of tumor-infiltrating lymphocytesPredictive value of tumor-infiltrating lymphocytesSignificance of tumor-infiltrating lymphocytesStudy of tumor-infiltrating lymphocytesImmune-checkpoint inhibitor therapyImmune-mediated tumor eliminationEra of immunotherapyT cell dysfunctionBiomarkers of responseSolid tumor typesImmunotherapeutic approachesAntigen-reactiveTumor microenvironmentTumor typesClinical outcomesTumor eliminationClinical significanceSingle-cell transcriptomicsPredictive valueAnticancer mechanismClinical implicationsResistance mechanismsHarnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E, Tan D, Tan W, Ang H, Carbone D, Yee M, Shanmugam M, Huang X, Sethi G, Tan T, Lim L, Huang R, Ungefroren H, Giovannetti E, Tang D, Bruno T, Luo P, Andersen M, Qian B, Ishihara J, Radisky D, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper K, Shi T, Merghoub T, Krebs S, Kusumbe A, Davids M, Brown J, Kumar A. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. Journal Of Hematology & Oncology 2025, 18: 6. PMID: 39806516, PMCID: PMC11733683, DOI: 10.1186/s13045-024-01634-6.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionTumor microenvironmentCancer progressionTherapeutic resistanceCancer therapyTumor microenvironment componentsTumor microenvironment modulationModulation of epithelial-mesenchymal transitionPromote tumor growthImprove treatment efficacyTumor microenvironment signalsTargeted cancer therapyTarget various componentsTherapeutic challengeTreatment responseTumor growthPromote metastasisTherapeutic strategiesTreatment efficacyEpithelial cellsMesenchymal traitsCancer cellsExtracellular matrix componentsCancerResistance mechanismsSociety for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
Taube J, Sunshine J, Angelo M, Akturk G, Eminizer M, Engle L, Ferreira C, Gnjatic S, Green B, Greenbaum S, Greenwald N, Hedvat C, Hollmann T, Jiménez-Sánchez D, Korski K, Lako A, Parra E, Rebelatto M, Rimm D, Rodig S, Rodriguez-Canales J, Roskes J, Schalper K, Schenck E, Steele K, Surace M, Szalay A, Tetzlaff M, Wistuba I, Yearley J, Bifulco C. Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing. Journal For ImmunoTherapy Of Cancer 2025, 13: e008875. PMID: 39779210, PMCID: PMC11749220, DOI: 10.1136/jitc-2024-008875.Peer-Reviewed Original ResearchConceptsSociety for ImmunotherapyMultiplex immunohistochemistrySociety for Immunotherapy of CancerImmunotherapy of cancerImmune cell subsetsPractice guidelinesCell subsetsTumor microenvironmentGeneration of robust dataTask ForceComplex immunophenotypeAcademic centersMarker expressionMIHC/IFClinical useClinical implementationImmunohistochemistryQuantitative image analysisImmunofluorescenceDiagnostic companiesRobust dataAssayImage analysisManagement considerationsStaining protocol
2024
Mechanisms of immunotherapy resistance in small cell lung cancer
Nie Y, Schalper K, Chiang A. Mechanisms of immunotherapy resistance in small cell lung cancer. Cancer Drug Resistance 2024, 7: n/a-n/a. PMID: 39802951, PMCID: PMC11724353, DOI: 10.20517/cdr.2024.154.Peer-Reviewed Original ResearchSmall-cell lung cancerImmune checkpoint inhibitorsSociety for Immunotherapy of CancerImmunotherapy resistanceTumor microenvironmentPrimary resistanceAcquired resistancePrimary resistance to immune checkpoint inhibitorsLung cancerResistance to immune checkpoint inhibitorsMechanisms of immunotherapy resistanceSmall cell lung cancerImmunosuppressive immune cellsImmunotherapy to chemotherapyResistance to immunotherapySociety for ImmunotherapyImmunotherapy of cancerAggressive neuroendocrine tumorCell lung cancerCheckpoint inhibitorsTumor immunogenicityEffective immunotherapyNeuroendocrine tumorsPoor prognosisAntigen presentationCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, Le J, Montesion M, Palmer R, Jahchan N, Juan J, Min C, Yu Y, Pan X, Arbour K, Vokes N, Schmidt S, Molkentine D, Owen D, Memmott R, Patil P, Marmarelis M, Awad M, Murray J, Hellyer J, Gainor J, Dimou A, Bestvina C, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian M, Sacher A, Lau S, Saltos A, Rotow J, Johnson R, Liu C, Stewart T, Goldberg S, Killam J, Walther Z, Schalper K, Davies K, Woodcock M, Anagnostou V, Marrone K, Forde P, Ricciuti B, Venkatraman D, Van Allen E, Cummings A, Goldman J, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok J, Segal J, Ritterhouse L, Neal J, Lacroix L, Elamin Y, Negrao M, Le X, Lam V, Lewis W, Kemp H, Carter B, Roth J, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula A, Parra Cuentas E, Behrens C, Wistuba I, Zhang J, Blumenschein G, Gay C, Byers L, Gibbons D, Tsao A, Lee J, Bivona T, Camidge D, Gray J, Leighl N, Levy B, Brahmer J, Garassino M, Gandara D, Garon E, Rizvi N, Scagliotti G, Wolf J, Planchard D, Besse B, Herbst R, Wakelee H, Pennell N, Shaw A, Jänne P, Carbone D, Hellmann M, Rudin C, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson M, Wong K, Huang A, Winslow M, Rosen M, Winters I, Papadimitrakopoulou V, Cascone T, Jewsbury P, Heymach J. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 2024, 635: 462-471. PMID: 39385035, PMCID: PMC11560846, DOI: 10.1038/s41586-024-07943-7.Peer-Reviewed Original ResearchNon-small-cell lung cancerImmune checkpoint blockadeTumor suppressor genePD-L1Advanced non-small-cell lung cancerCD8+ cytotoxic T cellsSuppressor geneCD4+ effector cellsDual immune checkpoint blockadeMouse modelPD-L1 inhibitor durvalumabSuppressive myeloid cellsPD-L1 inhibitorsImmune-related toxicitiesPD-(L)1 inhibitorsAnti-tumor efficacyCytotoxic T cellsMyeloid cell compartmentAdverse tumor microenvironmentAssociated with higher ratesAnti-tumor activityLoss of Keap1CTLA4 inhibitorsSTK11 alterationsCheckpoint blockadeEP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer
Ermer T, Kim S, Goldberg S, Zolfaghari E, Blasberg J, Boffa D, Herbst R, Politi K, Schalper K, Dacic S, Woodard G. EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s543-s544. DOI: 10.1016/j.jtho.2024.09.1007.Peer-Reviewed Original ResearchP3.13D.07 Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade
Chiang A, Matera R, Ashley K, Rajendran B, Schalper K. P3.13D.07 Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade. Journal Of Thoracic Oncology 2024, 19: s362. DOI: 10.1016/j.jtho.2024.09.652.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
HIC ID1603017333RoleSub InvestigatorPrimary Completion Date06/20/2026Recruiting Participants
News
News
- January 17, 2025Source: Nature
Biological and Clinical Significance of Tumor-Infiltrating Lymphocytes in the Era of Immunotherapy: A Multidimensional Approach
- November 13, 2024
Public School Students Explore Careers at Annual Yale Pathology Day
- May 06, 2024
Study Uncovers at Least One Cause of Roadblocks to Cancer Immunotherapy
- November 28, 2023
New Advanced Diagnostic Tests Lab to Perform, Interpret Clinical-grade Molecular Testing of Biomarkers
Get In Touch
Contacts
Locations
Fitkin Memorial Pavilion
Academic Office
789 Howard Avenue, Ste FMP, Rm 117
New Haven, CT 06519
Brady Memorial Laboratory
Lab
310 Cedar Street, Ste BML, Rm 113
New Haven, CT 06510
General Information
203.785.7792